We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

5 hedge funds and large institutions have $29.2K invested in PDL BioPharma, Inc. in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more capital invested

Capital invested by funds: $29.2K → $29.2K ($0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

17% less funds holding

Funds holding: 65 (-1)

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.06%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

PDLI Hedge Fund Activity: Q2 2026 in Review

5 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2026, worth a combined $29.2K — unchanged from a quarter earlier.

Fund positioning in PDLI was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

  • 5 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2026, down from 6 in Q1 2026.
  • Funds reported $29.2K of PDL BioPharma, Inc. stock for Q2 2026, unchanged quarter-over-quarter.
  • 1 fund opened new PDL BioPharma, Inc. positions in Q2 2026 and 1 closed out, a net change of 0 holders.

Based on aggregated 13F filings for Q2 2026.